glucagon has been researched along with pioglitazone in 19 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 4,338 | 824 | 2,277 |
| Protein | Taxonomy | glucagon (IC50) | pioglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
| Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
| Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
| Bile salt export pump | Homo sapiens (human) | 0.337 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Giacca, A; Kawamori, R; Lekas, M; Matsuhisa, M; Rodgers, CD; Shi, ZQ; Vranic, M; Wan, C | 1 |
| Christiansen, A; Holst, JJ; Madsbad, S; Zander, M | 1 |
| Croom, DK; Lenhard, JM; Minnick, DT | 1 |
| Baldi, S; Buzzigoli, E; Casolaro, A; Ciociaro, D; Ferrannini, E; Frascerra, S; Gastaldelli, A; Mari, A; Nannipieri, M; Pettiti, M | 1 |
| Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P | 2 |
| Bai, XP; DU, RQ; Li, HL; Lou, DJ; Pan, L; Wang, B; Xiao, JZ; Yang, WY | 1 |
| Ahrén, B | 1 |
| Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Ravikumar, B; Taylor, R | 1 |
| Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Takeuchi, K | 1 |
| Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R | 1 |
| Ahrén, B; Alba, M; Goldstein, BJ; Guan, Y; Inzucchi, SE; Kaufman, KD; Mallick, M; O'Neill, EA; Williams-Herman, DE; Xu, L | 1 |
| Gao, Z; Ke, B; Wei, X; Ye, J; Ye, X; Zhao, Z | 1 |
| Hamamoto, S; Hashiramoto, M; Hirukawa, H; Kaku, K; Kaneto, H; Kimura, T; Kohara, K; Okauchi, S; Shimoda, M; Tawaramoto, K | 1 |
| Li, YC; Li, YJ; Qiao, JY; Shen, JD; Wei, Y | 1 |
| Abdelaziz, RR; Abdelhamid, AM; Salem, HAA | 1 |
| Chae, YN; Jung, IH; Kim, MK; Kim, TH; Lee, JH | 1 |
| Arriaga, Y; Beg, MS; Gupta, A; Karri, S; Khosama, L; Mansour, J; Meyer, J; Scherer, PE; Stern, JH; Syed, S; Verma, U | 1 |
| Alimogullari, E; Bilginoglu, A; Cayli, S; Nakkas, H; Piskin, I | 1 |
1 review(s) available for glucagon and pioglitazone
| Article | Year |
|---|---|
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
5 trial(s) available for glucagon and pioglitazone
| Article | Year |
|---|---|
Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptide Fragments; Pioglitazone; Protein Precursors; Thiazolidinediones | 2004 |
Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Tolerance Test; Glycated Hemoglobin; Glycolysis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Lactates; Male; Middle Aged; Pioglitazone; Thiazolidinediones | 2007 |
Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glycerol; Glycogenolysis; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Liver; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazolidinediones | 2008 |
Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
Topics: Abdominal Fat; Adult; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liver; Magnetic Resonance Spectroscopy; Male; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Pioglitazone; Postprandial Period; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Middle Aged; Pioglitazone; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
13 other study(ies) available for glucagon and pioglitazone
| Article | Year |
|---|---|
The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.
Topics: Animals; Biological Transport; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dogs; Glucagon; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Topics: Aging; Animals; Blood Glucose; Cell Membrane; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Hemoglobins; Hypoglycemic Agents; Insulin; Kidney; Liver; Male; Metformin; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Precursors; Rats; Rats, Zucker; Thiazolidinediones | 2004 |
[The relationship between islet alpha cell insulin resistance and inflammatory pathway activation and its mechanism].
Topics: Animals; Fatty Acids, Nonesterified; Glucagon; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Islets of Langerhans; Male; Pioglitazone; Random Allocation; Rats; Rats, Sprague-Dawley; Signal Transduction; Thiazolidinediones | 2007 |
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose Clamp Technique; Glycerol; Heparin; Humans; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2008 |
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cell Degranulation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Eating; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Mice; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Topics: Abdominal Muscles; Adult; Aged; Bezafibrate; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2010 |
Regulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice.
Topics: Animals; Blood Glucose; Cell Line, Tumor; Diet, High-Fat; Gene Expression; Glucagon; Hepatocytes; Hypoglycemic Agents; Insulin; Insulysin; Liver; Mice; Mice, Inbred C57BL; Obesity; Palmitic Acid; Pioglitazone; RNA, Messenger; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2014 |
Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.
Topics: Animals; Apoptosis; Blood Glucose; Caspases; Cell Proliferation; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Ki-67 Antigen; Liraglutide; Male; Mice; Mice, Transgenic; Organ Size; Pioglitazone; Proto-Oncogene Proteins c-bcl-2; RNA, Ribosomal, 18S; Thiazolidinediones; Time Factors; Triglycerides | 2015 |
Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress.
Topics: Animals; Behavior, Animal; Blood Glucose; Corticosterone; Curcumin; Depression; Disease Models, Animal; Glucagon; Glucose Tolerance Test; Insulin; Insulin Resistance; Leptin; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Stress, Psychological; Thiazolidinediones | 2017 |
Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucagon; Glutathione; Glycated Hemoglobin; Insulin; Male; Malondialdehyde; Nitric Oxide; Nitriles; Pancreas; Pioglitazone; Pyrrolidines; Rats, Sprague-Dawley; Streptozocin; Superoxide Dismutase; Thiazolidinediones; Vildagliptin | 2018 |
Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Fasting; Glucagon; Glucose; Hep G2 Cells; Humans; Liver; Male; Mice; Pioglitazone; Piperazines; Thiazolidinediones | 2018 |
Fasting and Glucose-Stimulated Changes in Plasma Glucagon in Pancreatic Cancer: Potential Biomarkers for Detection?
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pancreatic Neoplasms; Pioglitazone | 2019 |
Effect of pioglitazone on the expression of ubiquitin proteasome system and autophagic proteins in rat pancreas with metabolic syndrome.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Proliferation; Glucagon; Insulin; Male; Metabolic Syndrome; Microtubule-Associated Proteins; Pancreas; Pioglitazone; Proteasome Endopeptidase Complex; Rats, Wistar; Ubiquitin | 2021 |